The results showed that with treatment of compound 5i, the PI3K/AKT/mTOR pathway was down-regulated in both H460 and A549 lung cancer cells in a dose-dependent manner (Fig. 3c), but not in H1975 lung cancer cells (Fig. S2e). The gene discussed is MTOR; the disease is lung carcinoma.